Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Myriad Genetics, Inc.    MYGN   US62855J1043

SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Analysis summary4-Traders Strategies 

Myriad Genetics, Inc. : Near a solid support area

02/19/2013 | 09:00am
Opinion : Bullish above USD 24.2
Target price : USD 26.1
Stop loss: USD 23.6
NASDAQ
Pharmaceuticals - Generic / Specialty

Myriad Genetics' share price was heavily penalized and is now in an oversold situation near to a solid support area.

Myriad Genetics is technically oversold and is near to the USD 24.2 support. This situation gives credit to a potential technical rebound. Thus, the stock could find new energy and would rise towards the next USD 26.1 resistance.

So as to make the most of a potential technical rebound of Myriad Genetics, it seems opportune to take a long position at the current price. A confirmation of this pattern would enable the security to reach the USD 27.62 resistance, with a potential gain of 13.2 %. Investors should not insist under USD 24.19 and place a stop loss order under this threshold.

Myriad Genetics, Inc. : Myriad Genetics, Inc. : Near a solid support area
Copyright (c) 2014 4-Traders.com



React to this article

Disclaimer: 4-traders.com is a website published by SURPERFORMANCE SAS. Surperformance or 4-traders.com is not a registered broker-dealer nor a registered investment adviser. You understand that this web site and its content is furnished for your personal, noncommercial, informational purposes only, and that no mention of a particular security in this website constitutes a recommendation to buy, sell, or hold any other security, nor that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Surperformance and 4-traders.com services will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. Information regarding trading and investment as provided by Surperformance professional is not tailored to the investment needs of any specific person. You acknowledge that you are responsible for your own financial decisions and should seek a registered financial agent depending on your own risk tolerance to advise you on your personal trading activities.

Advertisement
Financial Ratios

Size 2014e 2015e
Capitalization 2 781 M$ -
Company Value 2 798 M$ 2 803 M$
Valuation 2014e 2015e
PER (Price / EPS) 17,4x 19,0x
Capitalization / Revenue 3,65x 3,55x
EV / Revenue 3,68x 3,58x
EV / EBITDA 9,79x 11,1x
Yield (DPS / Price) - -
Profitability 2014e 2015e
Operating Margin (EBIT / Sales) 35,9% 31,3%
operating Leverage (Delta EBIT / Delta Sales) 0,82x -
Net Margin (Net Profit / Revenue) 22,2% 18,9%
ROA (Net Profit / Asset) 25,8% 22,9%
ROE (Net Profit / Equities) 21,6% 20,5%
Rate of Dividend - -
Balance Sheet Analysis 2014e 2015e
CAPEX / Sales   1,75% 1,70%
Cash Flow / Sales (Taux d'autofinancement) 24,6% 24,6%
Capital Intensity (Assets / Sales) 0,86x 0,82x
Financial Leverage (Net Debt / EBITDA) 0,06x 0,09x
Income Statement Evolution
Myriad Genetics, Inc. : Income Statement Evolution
More Financials
EPS Revisions
Myriad Genetics, Inc. : EPS Revisions
Dynamic quotes  
ON
| OFF